Evidence map›Paper›PMID 30918190›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Cytokine Profile in Sweet's Syndrome under the Treatment of Pulmonary Toxoplasmosis Complicated with Myelodysplastic Syndrome.

Yukimasa Matsuzawa, Eisuke Adachi, Atsuko Takahashi, Hidenori Sato, Lay Ahyoung Lim, Tsunehiko Komatsu, Tomohiko Koibuchi, Tokiko Nagamura-Inoue, Arinobu Tojo, Hitomi Nagayama and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. New Practical Aspects of Sweet Syndrome.American journal of clinical dermatology · 2022
    Review
  6. Neutrophilic Dermatosis in Myelodysplastic Syndrome and Chronic Active Hepatitis C.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yukimasa MatsuzawaDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Eisuke AdachiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Atsuko TakahashiDepartment of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo, Japan.
Hidenori SatoDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Lay Ahyoung LimDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Tsunehiko KomatsuDepartment of Hematology, Joban Hospital of Tokiwakai Group, Japan.
Tomohiko KoibuchiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Tokiko Nagamura-InoueDepartment of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo, Japan.
Arinobu TojoDepartment of Hematology/Oncology, Research Hospital The Institute of Medical Science, The University of Tokyo, Japan.
Hitomi NagayamaDepartment of Hematology, Teikyo University Chiba Medical Center, Japan.
Hiroshi YotsuyanagiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JPTeikyo University Chiba Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein describe a case of Sweet's syndrome (SS) in a patient being treated for pulmonary toxoplasmosis complicated with myelodysplastic syndrome (MDS). The patient's SS developed after the pulmonary toxoplasmosis improved following treatment. We searched his cytokine profiles comprehensively using a bead-based immunoassay. The results showed no elevation of interleukin (IL)-2, interferon (IFN)-γ or IL-17A, and IL-6 was only observed to have increased at the onset of SS, suggesting that the pulmonary toxoplasmosis had been well controlled and that chronic inflammation may have been the cause of SS. Pulmonary toxoplasmosis is an extremely rare occurrence. The cytokine profile can help to clarify the pathological condition of SS and MDS complicated with severely invasive infectious diseases.

Indexed as

AgedAntiprotozoal AgentsCytokinesFemaleHumansMyelodysplastic SyndromesSweet SyndromeToxoplasmosisAntiprotozoal AgentsCytokinescytometric bead arraymyelodysplastic syndromeSweet's syndrometoxoplasmosis

Identifiers

PMID30918190
PMCPMC6702012
OpenAlexW2925336748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.